Last Updated: July 10, 2026

Patent: 8,771,706

✉ Email this page to a colleague

Summary for Patent: 8,771,706

Title:	Anti-RSV immunogens and methods of immunization
Abstract:	Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof.
Inventor(s):	Anderson Larry J., Haynes Lia M., Tripp Ralph A.
Assignee:	The United States of America, as represented by the Secretary of the Department of Health and Human Services
Application Number:	US13763822
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	United States Patent 8,771,706: Claim Scope, Validity Risks, and US Patent Estate Landscape Executive summary: USP 8,771,706’s enforceable scope is determined by (1) the independent claim structure and key limitation ordering (system/method, composition, or process), (2) whether dependent claims add discrete technical constraints (e.g., specific formulation parameters, dosing regimens, device architecture, or process steps), and (3) how the claim limitations map to the prior art cited during prosecution and to claim construction outcomes in any related litigation. Without the actual claim text, an accurate element-by-element construction, novelty/obviousness analysis, and “design-around” guidance cannot be produced. No analysis can be provided because the prompt does not include the claims beyond “The claims are:” and provides no claim language, figures, prosecution citations, assignee, priority data, or USPTO publication family information. More… ↓ ⤷ Start Trial

Details for Patent 8,771,706

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769	May 31, 2023	⤷ Start Trial	2033-02-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for Patent: 8,771,706

United States Patent 8,771,706: Claim Scope, Validity Risks, and US Patent Estate Landscape

Make Better Decisions: Try a trial or see plans & pricing